Genomic data is being integrated into clinical trials—sometimes not so successfully, and sometimes very, very successfully.
Discoveries driven by genomic data could dramatically increase the number of biomarkers available for use in clinical trials.
The world's oncology pipeline is rapidly growing, with nearly 40% of the global clinical pipeline focused on immuno-oncology.
Unsupervised genomic clustering can pinpoint safety and efficacy signals quickly and accurately...so what is unsupervised genomic clustering?
Today’s guest post is from Reinhard von Roemeling, board certified oncologist and former SVP of global oncology at EMD-Serono/Merck KGaA.